Bertilimumab

N/A

Report date: 2025/11/26 20:00:44

Base Information

Drug NameBertilimumab
Drug Alias NameiCo-008CAT-213
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionEotaxin inhibitors
TargetsEotaxin
Therapy Area/IndicationsPemphigoid, BullousColitis, Ulcerative
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesIsrael
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedimmune Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsPemphigoid, BullousColitis, Ulcerative

Other Information

ATC CodeN/A
Related LinksWikipedia